William Blair Sticks to Their Buy Rating for InterDigital (IDCC)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Bhatia is a 4-star analyst with an average return of 3.8% and a 50.54% success rate. Bhatia covers the Technology sector, focusing on stocks such as InterDigital, Five9, and Atlassian.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for InterDigital with a $235.50 average price target.
Based on InterDigital's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $210.51 million and a net profit of $115.6 million. In comparison, last year the company earned a revenue of $263.54 million and had a net profit of $81.65 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. Fifteen products delivered at least double-digit sales growth in the second quarter. Outlook Following the strong quarterly performance, Amgen raised fiscal year 2025 adjusted earnings guidance from $20.00-$21.20 per share to $20.20-$21.30 versus the consensus of $20.89. The company raised sales outlook from $34.30 billion-$35.70 billion to $35 billion-$36 billion versus the consensus of $35.29 billion. MariTide in Focus Despite the positive financial results, investor focus remains squarely on the company's experimental weight-loss drug, MariTide. A William Blair analyst noted that investors are 'hyper-focused' on the drug's progress. Part 2 of the Phase 2 chronic weight management study is ongoing in obese patients, with or without type 2 diabetes. Data readout is anticipated in the fourth quarter of 2025. View more earnings on AMGN A Phase 2 study investigating MariTide for type 2 diabetes is ongoing in adults with and without obesity. Data readout is anticipated in the fourth quarter of 2025. Analyst Matt Phipps of William Blair said, 'Given the trial is solely focused on the maintenance setting, we do not believe it will address the key question of tolerability that investors continue to debate.' Analyst Phipps says Amgen shares are up 15% year-to-date, although it remains volatile as investors debate clinical updates with MariTide given the significant market opportunity and competitive landscape. 'We believe Amgen has had meaningful clinical and commercial success with assets including Repatha, Evenity, Blincyto, Tezspire, Imdelltra, and Uplizna that support continued upside on top of the potentially differentiated profile of MariTide, and therefore reiterate our Outperform rating.' Amgen has some near-term headwinds from legacy products, including the recent launch of a biosimilar to Prolia and Xgeva at the end of May 2025 (recent settlement with Sandoz), and the difficulties in gaining more market share with the biosimilar franchises, but the analyst believes clinical catalysts over the next 6 to 12 months will provide meaningful reasons for investor excitement about the long-term growth prospects of the company. Check out . Price Action: AMGN stock is trading lower by 5.10% to $284.97 at last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for AMGN Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for AMGN View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? AMGEN (AMGN): Free Stock Analysis Report This article Amgen Stock Sinks As Market Eyes MariTide's Next Move originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Business Insider
4 hours ago
- Business Insider
Bitcoin Just Beat Amazon. Is Apple Next?
On July 14, Bitcoin officially became more valuable than Amazon (AMZN). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. After jumping nearly 13% in just a week, the world's most famous cryptocurrency crossed $122,600 and hit a market cap of roughly $2.4 trillion. That pushed it ahead of Amazon's estimated $2.3 trillion valuation, making Bitcoin one of the five most valuable assets on Earth. Not bad for a digital token some still call 'fake internet money.' Bitcoin ETFs Fueled the Surge The move wasn't driven by hype alone. A record wave of inflows into spot Bitcoin ETFs played a huge role. In two back-to-back trading days, U.S.-listed Bitcoin funds pulled in over $1 billion each, the strongest streak since they launched in early 2024. These ETFs have become the gateway for traditional investors, from hedge funds to pension managers, to get exposure to Bitcoin without touching crypto wallets or exchanges. BlackRock's fund (IBIT) alone now holds more than $80 billion worth of BTC. Washington Cleared the Way But it wasn't just the money pouring in. Policy momentum has finally turned in Bitcoin's favor. In July, Washington held what's now being called 'Crypto Week' — a slate of pro-crypto legislation that included clearer rules, protections for digital asset investors, and a much-needed signal from lawmakers: crypto isn't going away. That rare bipartisan alignment gave institutions the green light to step in more aggressively. Trump Helped Bitcoin's Ascent Then there's the broader backdrop. The Trump administration has leaned crypto-friendly, the dollar has been weakening, and many investors are looking for alternatives to centralized finance. Bitcoin, with its hard cap of 21 million coins and borderless design, is looking more attractive. It's become a structural piece of the new financial system. Bitcoin Behaves Like a Big Tech Stock And that's probably the most important shift underway. Bitcoin isn't being treated like a fringe asset anymore. It's moving in sync with tech stocks and showing up in institutional portfolios. One study earlier this year found that Bitcoin's correlation with the Nasdaq and S&P 500 reached 0.87 — higher than it's ever been. Essentially, Bitcoin is a risk asset being priced in alongside the biggest names in tech. Bitcoin's Scale Is Massive Of course, the narrative is about more than just movement. It's about magnitude. Bitcoin's price in 2010 was about ten cents. Fifteen years later, it hit a record high of $122,000. That's a 1.2 million percent return. There's no other asset in modern financial history with a trajectory like that. What started as a cypherpunk experiment is now being compared to Apple (AAPL) and Microsoft (MSFT) in size. A big reason behind that rise is scarcity. Bitcoin's 21 million supply cap is hard-coded. No CEO, no central bank, no stimulus committee can inflate it. That scarcity mirrors gold; but unlike gold, Bitcoin is digital, transparent and liquid around the clock. It's become a hedge, a reserve, and for many companies, a treasury asset. And companies are buying. As of this year, more than 265 private and public firms hold Bitcoin, accounting for about 4% of total supply. Bitcoin ETFs, collectively, hold around 6.6%. These are not niche allocations anymore. They're foundational bets on where the financial world is headed. Bitcoin Could Be Gunning for Apple Next To do that, it would need to jump another 15%–35%, depending on which company you're measuring against. That would push Bitcoin's market cap toward the $3 trillion range. And based on some of the current momentum, analysts are warming to that possibility. Several institutional forecasts now place Bitcoin above $140,000 by the end of the year, with some pointing toward $180,000–$200,000 if ETF demand holds strong. That's the bull case. But getting there isn't guaranteed. If ETF inflows slow, or if U.S. policy changes up once again, Bitcoin could lose steam. Its price is still sensitive to interest rate moves and macro conditions. And for all its mainstream progress, the asset remains volatile in both directions. At the time of writing, Bitcoin is sitting at $114,086.66.
Yahoo
4 hours ago
- Yahoo
Crawford & Company® to Participate in the William Blair Insurance, Banking & Wealth Technology Conference
ATLANTA, August 06, 2025--(BUSINESS WIRE)--Crawford & Company® (NYSE: CRD-A and CRD-B) is pleased to announce that the Company will take part in the 2025 William Blair Insurance, Banking & Wealth Technology Virtual Conference on Tuesday, August 12, 2025. Pat Van Bakel, President, North America Loss Adjusting will be participating in the Future of Claims Panel at 3:45 pm ET and management will be available for one-on-one meetings on August 13, 2025. About Crawford® Based in Atlanta, Crawford & Company (NYSE: CRD-A and CRD-B) is a leading global provider of claims management and outsourcing solutions to insurance companies and self-insured entities with an expansive network serving clients in more than 70 countries. The Company's two classes of stock are substantially identical, except with respect to voting rights for the Class B Common Stock (CRD-B) and protections for the non-voting Class A Common Stock (CRD-A). More information is available at Tag: Crawford-Investor-News-and-Events, Crawford-Financial View source version on Contacts Media Contacts: mediarelations@ Lynn Cufley+44 7585 Katie Cline+1 470 792 Investor Contact:Jennifer Belodeau/Rosalyn ChristianIMS Investor Relations203 972 9200crawford@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
